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Background: The recent increase in popularity of acellular dermal matrix assistance
in immediate expander/implant breast reconstruction has led to variety of viewpoints.
Many studies are published indicating an increase in complications with the use of
acellular dermal matrix, while others indicate there is no increase in complications.
Methods: This meta-analysis utilizes information from available studies that directly
compare one speciﬁc type of acellular dermal matrix with traditional methods of im-
mediate expander/implant breast reconstruction. Eight studies were found through a
meticulous literature search that met these criteria. Results: There was more than a
2-fold increase in the number of infections and explanations in the acellular dermal
matrix group compared to the control. There was a 3-fold increase in seroma formation
in the acellular dermal matrix group compared to the control. There was a signiﬁcant
differenceofintraoperativeﬁllvolumesbetweentheacellulardermalmatrixgroupcom-
pared to the control. Conclusions: This study illustrates that after pooling all available
date regarding the use of acellular dermal matrix in immediate expander/implant breast
reconstruction there appears to be an increased rate of complications. However, the
increased intraoperative ﬁll volume may lead to ultimately greater patient satisfaction.
The use of AlloDerm (LifeCell, Branchburg, New Jersey), an acellular dermal matrix
(ADM), in breast reconstruction to facilitate complete coverage of the implant/expander
gained popularity in 2005.1 The introduction of this biomaterial has made it possible to
provide complete tissue expander coverage without dissection of the serratus anterior or
rectus abdominis muscle/fascia. In addition, it has been shown that when using ADM, the
intraoperative tissue expander ﬁll volume was increased and the total number of expan-
sions needed was decreased.2 However, ADM use does not come without complications;
increased rates of infection and seroma formation have been linked with ADM use.3-5
Five years following the adoption of ADM in expander/implant breast reconstruction,
it is still unclear whether its use presents an increased risk of infection and/or seroma
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formation. The results of most individual studies are oftentimes difﬁcult to interpret. The
authors believe that a more deﬁnitive conclusion may be drawn by examining these stud-
ies through a systematic review and pooling data from these studies into a meta-analysis.
Selected studies were examined for rates of complications in patients undergoing ADM-
assisted and conventional expander/implant breast reconstruction. A literature search was
performed to select high-quality observational studies, the highest level of evidence cur-
rently available, that examine the relevant data. The level of evidence of the resulting
systematic review of these studies is classiﬁed as 3a (Based on the University of Oxford’s
Centre for Evidence Based Medicine levels of evidence6). Systematic reviews are usually
based on randomized controlled trials to achieve a level of evidence of 1a. Because of the
nature of the studies in this systematic review, Stroup et al’s consensus article regarding
meta-analyses of observational studies was used in the reporting of methods and results of
this study.7 This method has been validated previously for the reporting of observational
studies in the ﬁeld of plastic and reconstructive surgery.8 Guidelines compiled speciﬁcally
for systematic reviews and meta-analyses in plastic surgery literature were also followed.9
Search Strategy
Oneauthor(I.C.H.)conductedallinitialsearches.PubMedwassearchedwiththekeywords,
“alloderm,” “biocompatible materials,” “acellular dermal matrix,” “breast,” “expander im-
plant,” and “infection” through February 2011. Daily updates of new papers that matched
the search criteria were provided by e-mail. The Cochrane Central Register of Controlled
Trials revealed 4 ongoing studies examining the use of ADM in breast reconstruction. In
addition, reference lists were scrutinized to ﬁnd any studies that may have been inadver-
tently excluded in the initial search. Abstracts were initially used to select relevant articles
utilizing inclusion criteria (Table 1). Full-text articles were retrieved and submitted to the
exclusion criteria (Table 2). A diagram of the search process is presented in Figure 1. In
addition a brief literature search was performed to identify several other ADM products
and their clinical applications.
Table 1. Inclusion criteria
Clinical human study
Postmastectomy
Breast reconstruction
AlloDerm utilized
English language
Table 2. Exclusion criteria
Method other than tissue expander/implant breast reconstruction
No comparison between ADM group and control
Previously published data
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Figure 1. Study acquisition.
DATA EXTRACTION
All studies included in the meta-analysis evaluate the rates of complications in ADM-
assisted compared to traditional implant/expander breast reconstruction following mas-
tectomy. All data were extracted directly from each study. Two researchers evaluated and
independently extracted data from each study using a standardized form. The researchers
were not blinded to the study being examined as this has been shown to be unnecessary.10
STATISTICAL ANALYSIS
Statistical analysis was performed utilizing Review Manager (RevMan [Computer pro-
gram], Version 5.0, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collabo-
ration, 2008). A ﬁxed effect model and the Mantel-Haenszel test was utilized to provide
pooled odds ratios (ORs) for the variables under examination.
419ePlasty VOLUME 11
RESULTS
Seven observational studies were found to ﬁt the inclusion and exclusion criteria.2-4,11-14
One study5 reported only explantation rates and was only included in that analysis. Table 3
provides a summary of the characteristics of each study.
Table 3. Characteristics of each study included
No. of Mean age, Mean body Infections, Seromas, Hematomas, Explantation,
Source breasts y mass index n (%) n (%) n (%) n (%)
Antony
et al
ADM 153 44.5∗ 23.8 5 (3.3) 11 (7.2) 3 (2.0) 9 (5.8)
Control 2910 48.1∗ 26.3 38 (1.3) 47 (1.6) 26 (0.9) 55 (1.9)
Chun et al ADM 269 47 25.5 24 (8.9) 38 (14.1) 6 (2.2) 16 (5.9)
Control 146 46.2 23.8 3 (2.1) 4 (2.7) 2 (1.4) 1 (0.7)
Lanier et al ADM 52 51 29.8 15 (28.9) 8 (15.4) 0 (0) 10 (19.2)
Control 75 50 24.7 9 (12) 5 (6.7) 0 (0) 4 (5.3)
Liu et al ADM 266 NA 24.9 18 (6.7) 19 (7.1) 1 (0.4) 13 (4.8)
Control 204 NA 24.8 5 (2.4) 8 (3.9) 0 (0) 5 (204)
Nahabedian ADM 100 46 NA 5 (5) NA NA 2 (2.0)
Control 376 NA NA 22 (5.85) NA NA 20 (5.3)
Preminger
et al
ADM 45 NA NA 3 (6.7) 3 (6.7) 1 (2.2) NA
Control 45 NA NA 1 (2.2) 2 (4.4) 0 (0) NA
Sbitany
et al
ADM 92 48.6 26.4 4 (8) 3 (6) NA 4 (4.3)
Control 84 51.7 28.2 3 (6) 3 (6) NA 3 (3.6)
ADM indicates acellular dermal matrix; BMI, body mass index; NA, not available.
∗Median.
In general, 3 studies2,11,12 reported no difference in the rate of complications and 4
studies3,4,13,14 reported an increased rate of complications between groups.
INCLUDED STUDIES
Antony et al13
This retrospective comparative study examines immediate 2-stage tissue expander breast
reconstruction over a 4-year period at a single institution. In this period, there were 153
breasts included in the ADM (AlloDerm) group and 2910 breasts included in the con-
trol group. The control group was deﬁned as a traditional musculofascial method. De-
scriptive characteristics are provided in Table 4. Notably, the mean BMI (body mass
index) for the non-ADM group was lower than the ADM group and the rate of preop-
erative radiation therapy was higher in the ADM group. No formal comparison between
ADM and control groups was performed. Outcomes examined included seroma, cellulitis,
hematoma, and premature explantation of the expander. Overall, there was an increased
incidence of complications noted in the ADM group. Age, BMI, and axillary dissec-
tion were determined to be independent risk factors for development of one or more
complications.
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Table 4. Characteristics of Antony et al
ADM Control
Median age 44.5 48.1
Mean BMI 23.8 26.3
Adjuvant/neoadjuvant chemotherapy, % 45.8 50.1
Preoperative radiation, % 15.6 11.1
Postoperative radiation, % 9.4 11.4
ADM indicates acellular dermal matrix; BMI, body mass index.
Chun et al3
This retrospective comparative study examines immediate breast reconstruction utiliz-
ing tissue expanders and implants over a 6-year period at a single institution. During
this period, there were 269 breasts included in the ADM (AlloDerm) group and 146
breasts in the control group. The control group was deﬁned as expanders/implants with
total submuscular coverage or partial submuscular coverage with corresponding partial
subcutaneous coverage. Within this group, 68 latissimus dorsi and 1 pedicled transverse
rectus abdominis muscle ﬂaps were included because they utilized a tissue expander or
an implant. Descriptive characteristics are provided in Table 5. All characteristics were
compared to ﬁnd signiﬁcant differences among groups. Notably, there was a signiﬁcant
(P = .002) difference between the BMI of the 2 groups and the mastectomy specimen
(P <. 001)weightof eachgroup. Outcomesexaminedincludedhematoma,seroma, necro-
sis, intraoperative ﬁll volume, and infection. Infection was broken down into minor (suc-
cessfully treated with outpatient antibiotics) and major infections (required admission),
both of which were combined to determine the rate of infection. Overall, there was an
increased rate of complications in the ADM group. Body mass index and the use of
ADM were determined to be signiﬁcant risk factors for the development of infection and
seroma.
Table 5. Characteristics of Chun et al
ADM Control
Mean age 47 46.2
Mean BMI 25.5 23.8
Preoperative chemotherapy, % 14.9 8.2
Postoperative chemotherapy, % 19 30.8
Preoperative radiation, % 8.7 5.2
Postoperative radiation, % 8.6 6.5
Mean mastectomy specimen weight, g 577.2 389.9
ADM indicates acellular dermal matrix; BMI, body mass index.
Lanier et al4
This retrospective comparative study examines immediate 2-stage tissue expander breast
reconstruction over a 3-year period at a single institution. During this period, 52 breasts
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were included in the ADM (AlloDerm) group and 75 breasts in the control group. The
control group was deﬁned as the creation of a subpectoral pocket and a lateral pocket
utilizing serratus anterior muscle. Descriptive characteristics are provided in Table 6. All
characteristics were compared to ﬁnd signiﬁcant differences among groups. Signiﬁcant
differences were noted in BMI (P <. 001) and mean breast tissue removed (P = .005)
between groups. Outcomes examined included seroma, hematoma, necrosis requiring re-
vision, capsular contracture, intraoperative ﬁll volume, and cellulitis or infection. Overall,
there was an increased rate of complications in the ADM group.
Table 6. Characteristics of Lanier et al
ADM Control
Mean age 51 50
Mean BMI 29.8 24.7
Preoperative chemotherapy, % 11.5 20
Postoperative chemotherapy, % 51.9 45.3
Preoperative radiation, % 5.8 9.3
Postoperative radiation, % 5.8 10.7
Mean mastectomy specimen weight, g 646 984
ADM indicates acellular dermal matrix; BMI, body mass index.
Liu et al14
This retrospective comparative study examines immediate 2-stage tissue expander breast
reconstruction over a 5-year period at a single institution. During this period, 266 breasts
were included in the ADM (AlloDerm) group and 204 breasts in the control group. The
control group was deﬁned as either total or partial submuscular placement of the expander.
Descriptive characteristics are provided in Table 7. Signiﬁcant differences were noted in
mean breast tissue removed (P = .0184). Outcomes included infection, implant removal,
skin ﬂap necrosis, seromas, intraoperative ﬁll volume, and hematomas. Overall, complica-
tions were higher in the ADM group.
Table 7. Characteristics of Liu et al
ADM Control
Mean BMI 24.9 24.8
Radiation, % 9.8 10.4
Mean mastectomy specimen weight, g 526.4 456.9
ADM indicates acellular dermal matrix; BMI, body mass index.
Nahabedian11
This retrospective comparative study examines breast reconstruction utilizing prosthetic
devicesoveraperiodof11years.Speciﬁcally,thisstudyexaminedtheratesofcomplications
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with and without chemotherapy and/or radiation. During this period, 100 breasts were
included in the ADM (AlloDerm) group and 376 breasts were included in the control
group. The control group was deﬁned as device placement beneath the pectoralis major
and lower mastectomy skin ﬂap. Few descriptive characteristics were included regarding
the patients. Outcomes examined included infection, implant removal, and ADM removal.
Overall, there was no difference in the rate of complications between groups.
Preminger et al12
This matched, retrospective cohort study examines immediate tissue expander implant
breast reconstruction over a 2-year period. Matching criteria included median expander
size, history of radiation, and indication for mastectomy. Matched cohorts of 45 breasts
each were prepared. The experimental group utilized ADM (AlloDerm). The control group
was deﬁned as creation of a subpectoral pocket with elevation of the serratus anterior
and superior rectus abdominis muscle/fascia. Few descriptive characteristics were included
regarding the patients, but due to the matched cohort nature of the study, it can be assumed
that there are likely few differences between groups. Outcomes examined included seroma,
hematoma, intraoperative ﬁll volume, and cellulitis. For the purposes of the meta-analysis,
the rate of cellulitis was used as the rate of infection. Overall, there was no difference in
the rate of complications between groups.
Sbitany et al2
This retrospective comparative study examines tissue expander implant breast reconstruc-
tion over a 4-year period. During this period, 92 breasts were included in the ADM
(AlloDerm) group and 84 breasts were included in the control group. The control was
deﬁned as placement in a subpectoral pocket with elevation of the serratus anterior lat-
erally. Descriptive characteristics are provided in Table 8. No signiﬁcant differences were
found between these characteristics. Outcomes examined included seroma, cellulitis, in-
traoperative ﬁll volume, and infection requiring expander removal. For the purpose of this
meta-analysis, the rate of cellulitis was used as the rate of infection. Overall, there was no
difference in the rate of complications between groups. During the reporting of complica-
tions, the authors used the number of patients instead of the number of reconstructions. The
decision was made to utilize these values in terms of the number of reconstructions for the
purpose of this meta-analysis to avoid discrepancies in reporting.
Table 8. Characteristics of Sbitany et al
ADM Control
Mean age 48.6 51.7
Mean BMI 26.4 28.2
Postoperative radiation, % 12 6
ADMindicatesacellulardermalmatrix;BMI,bodymass
index.
423ePlasty VOLUME 11
Table 9. Commonly used dermal matrices
Used in Expander/
Hydration Implant Breast?
Brand Name Manufacturer Donor Donor Screening Status Description Reconstruction?
Alloderm LifeCell Human Own screening
modality
Dehydrated Processed
to remove
epidermis
and
dermal
cells
Yes
DermaMatrix Synthes Human MTF screening Dehydrated Processed
to remove
epidermis
and
dermal
cells
Yes
FlexHD Ethicon Human MTF screening Hydrated Processed
to remove
epidermis
and
dermal
cells
Yes
Permacol Covidien Porcine n/a Hydrated Processed
to remove
cells;
resulting
collagen
cross-
linked
No
Strattice LifeCell Porcine n/a Dehydrated Processed
to remove
cells
Yes
MTF indicates Musculoskeletal Transplant Foundation.
∗According to ofﬁcial product description.
META-ANALYSIS OF STUDIES
A forest plot of the OR of infection across all studies is provided in Figure 2. The meta-
analysis reports over a 2-fold increase in rate of infections for the ADM-assisted group
(OR of 2.33; 95% conﬁdence interval [CI], 1.55-3.49). A forest plot of the OR of seroma
formation across the 5 studies reporting this statistic is provided in Figure 3. There was
a 3-fold increase in the incidence of seromas in the ADM-assisted group (OR of 3.00;
95% CI, 1.96-4.61). A forest plot of the OR of tissue expander explantation across all
studies is provided in Figure 4. The meta-analysis reports over a two-fold increase in rate of
explantations for the ADM-assisted group (OR of 2.41; 95% CI, 1.59-3.64). A forest plot
of the mean difference of intraoperative ﬁll volumes of the tissue expanders is provided in
Figure 5. The meta-analysis reports a mean difference of 162 mL (95% CI, 148-177)
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Figure 2. Forest plot of rate of infections between groups. ADM indicates
acellular dermal matrix.
Figure 3. Forest plot of rate of seromas between groups. ADM indicates acel-
lular dermal matrix.
Figure 4. Forest plot of rate of explantations between groups. ADM indicates
acellular dermal matrix.
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Figure 5. Forest plot of mean intraoperative tissue expander ﬁll volume. Mean
standard deviation from the other studies were used if no standard deviation
was provided. ADM indicates acellular dermal matrix.
DISCUSSION
As breast reconstruction following mastectomy utilizing ADM becomes an acceptable
reconstructive option, it is important to understand the risks and beneﬁts of its use. In
the case of expander/implant breast reconstruction, several variables are important to the
end result and ultimately patient satisfaction. These include postoperative complications
such as infections, seromas, and the rate of expander explantation following one of these
complications. It has been previously found that the use of ADM in postmastectomy
immediate reconstructions results in high levels of patient satisfaction.15
While there is much in the current literature regarding ADM use in expander/implant
breast reconstruction, the majority focuses on the rates of complications and the dynamics
ofexpansion.1,16-21 Unfortunately,mostofthesepublicationsarecaseserieswithnocontrol
group.
It is oftentimes difﬁcult to evaluate the results of each individual study due to the
presence of confounding factors such as BMI, surgeon skill (both plastic surgeon and
breast surgeon), and unclear methods of study design. The goal of a systematic review and
meta-analysis is to utilize samples from different studies to minimize these confounding
variables. The 7 studies included in this analysis were split regarding whether complication
rates were higher in the ADM group. This presents a problem for the surgeon attempting to
determine the true risks and beneﬁts of the use of ADM. It is the goal of this meta-analysis
to pool all available data to obtain a clearer picture of the risks inherent with the use of
ADM in expander/implant breast reconstruction.
This meta-analysis demonstrates that ADM use in expander/implant reconstruction
results in increased rates of infection, seroma, hematoma, and explantation compared to a
control. This is not conceptually difﬁcult to understand given that ADM is a foreign body,
despite its biologic properties. Foreign bodies incite an inﬂammatory reaction that results
in increased rates of infection. Furthermore, Alloderm is considered an aseptic product as
opposed to sterile,providinga further risk of postoperativeinfection.This may explainwhy
itsuseisassociatedwithanincreasedriskofinfectiondespitethesimultaneoususeoftissue
expanders and implants, also foreign bodies. The difference is that the tissue expanders and
implants are sterile prior to introduction. The advantage provided by ADM is the eventual
ingrowth of vasculature that has the potential to provide the means for eliminating bacterial
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infection,11 although this process takes time leaving a period of time where the ADM may
be susceptible to infection. This does not preclude the use of ADM in breast reconstruction
as the beneﬁts may outweigh the risks reported by this study. These beneﬁts may include
decreased postoperative pain and morbidity, decreased operative time, increased initial
expander ﬁll volume, and an increased rate of expansion. This meta-analysis showed a
signiﬁcant difference between the ADM group and the control regarding intraoperative ﬁll
volume. This may lead to a fewer number of expansions and a earlier expander/implant
exchange procedure as evidenced in one of the studies.2
Weaknesses of this meta-analysis include the possible introduction of publication
bias and a slightly different deﬁnition of outcome measurements across studies. Through
our meticulous literature search we attempted to include all published data on the topic.
Unfortunately, researchers are less likely to publish unfavorable results, introducing a
degree of bias. An attempt was made to generalize outcome measurements throughout
each study as described in each synopsis. For instance, not all studies provided a strict
deﬁnition of seroma. This is a potential source of bias due to the fact that there are 2 types
of seromas, those which do not require treatment and those which do. While this study
only examined one brand of ADM, many other types exist. Products differ in dermal origin
(human/porcine), donor screening process, and method of preparation. A brief description
of commonly used dermal matrices used in breast reconstruction and abdominal wall repair
is illustrated in Table 9.22-27 Further studies will need to be performed to compare the
efﬁcacy of these products in breast reconstruction. As of now it is unclear how the different
processing methods and dermal origins may impact the complication rate in immediate
tissue expander implant breast reconstruction.
Clinical applications
While the ﬁnding that there is an increased rate of complications when ADM is utilized
does not preclude its use in breast reconstruction, it brings up several important points. It is
importantforthesurgeontobeknowledgeableregardingtheratesofpossiblecomplications
so that this information may be passed on to patients in a way that allows them to make the
mosteducateddecision.Onthesametoken,itisimperativetoexplainthestrengthsinherent
with the use of ADM in breast reconstruction. Less time is needed to spend raising muscle
ﬂaps and the patient may subsequently experience less postoperative pain when utilizing
ADM.
As in any reconstructive procedure, the surgeon must use their judgment when decid-
ing on an operative plan. This study simply attempts to clear up an intensely debated issue
in breast reconstruction. For a more deﬁnitive conclusion to be reached, a large multicen-
ter, randomized controlled trial must be organized examining not only the complications
following ADM use, but the beneﬁts as well.
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